Amivantamab is an anticancer drug that belongs to the class of medications called bispecific antibodies.FDA approved it on May 21, 2021, for the treatment of a type of lung cancer called non-small cell lung cancer (NSCLC). 

Amivantamab is an intravenously administered drug. It is used to treat non-small cell lung cancer (NSCLC), which spreads to other parts of the body and has certain changes in a gene called EGFR. It is also used if it cannot be removed by surgery and has worsened during or after treatment with other anticancer medications. 

It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein) for several hours. Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors. 

The common side effects of amivantamab are swelling in the face, hands, and feet, inflammation in the nails, constipation, nausea, vomiting, inflamed and sore mouth, musculoskeletal pain, cough, shortness of breath, and tiredness. Other common side effects include severe rashes in the skin, eye pain and infection, inflammation of the lungs, and infusion reactions. 

The drug is intended to cause lung inflammation.  Report to your physician if you face any symptoms of sudden difficulty in breathing, cough, or fever that may suggest inflammation of the lungs. Amivantamab can cause potential harm to the fetus; inform your physician if you are pregnant, suspecting, or planning for pregnancy before initiating the treatment. This injection may cause severe infusion reactions; notify your physician if you face any allergic reactions like itching, swelling in your face or hands, tingling in mouth or throat, chest tightness, difficulty in breathing, fever, chills, cough, sore throat, body aches, unusual bleeding, bruising, or weakness should be informed immediately. 

Inform your physician if you have kidney problems, liver or lung problems before initiating the therapy. This medicine may cause harm to the fetus hence use effective contraception during the treatment. Using an effective birth control method during the treatment and for 3 months after your last dose is necessary. Do not take this injection if you are allergic to amivantamab or any other ingredients of this medicine. This medicine is not recommended for children or young people below 18 years of age. Your healthcare professional may advise you to take certain blood tests to monitor the effectiveness and side effects of the therapy. 

Store amivantamab in the refrigerator (2°C to 8°C). Do not freeze. Keep the injection away from the reach of children and pets. If you have missed any dosing appointments, inform your doctor and schedule immediately. To reduce skin problems, limit sun exposure during and for 2 months after treatment, wear protective clothing, and apply sunscreen and moisturizers that are alcohol-free regularly on your skin and nails while taking this medicine. Contact your doctor or nurse immediately if you have eye pain or vision problems. Consult your doctor before using contact lenses when you are taking this medicine. Do not breastfeed during the treatment and for 3 months after the last dose. Your doctor may advise you to take certain tests to check for the effectiveness of the therapy. 

1. Rybrevant (amivantamab) 50mg/mL concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc). www.medicines.org.uk. [revised on 2021] [cited 2023 Apr 6]. Available from: https://www.medicines.org.uk/emc/product/13084/pil
2. HIGHLIGHTS OF PRESCRIBING INFORMATION - amivantamab. [revised on 2021] [cited 2023 Apr 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf
3. Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results from the CHRYSALIS Phase I Study. Journal of Clinical Oncology [revised on 2021 Aug 2] [cited 2023 Apr 6];39(30):JCO.21.00662. Available from: https://pubmed.ncbi.nlm.nih.gov/34339292/ 

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.